Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-4.04 Insider Own2.30% Shs Outstand348.92M Perf Week3.21%
Market Cap6.18B Forward P/E4.64 EPS next Y3.82 Insider Trans-65.24% Shs Float343.76M Perf Month12.09%
Income-1407.30M PEG- EPS next Q0.94 Inst Own66.80% Short Float9.93% Perf Quarter96.34%
Sales9.41B P/S0.66 EPS this Y-714.90% Inst Trans20.13% Short Ratio1.47 Perf Half Y30.41%
Book/sh11.13 P/B1.59 EPS next Y6.62% ROA-3.10% Target Price- Perf Year-22.49%
Cash/sh3.47 P/C5.11 EPS next 5Y-7.77% ROE-34.10% 52W Range8.31 - 32.74 Perf YTD21.97%
Dividend- P/FCF3.85 EPS past 5Y61.43% ROI-1.60% 52W High-45.92% Beta-0.36
Dividend %- Quick Ratio1.00 Sales past 5Y31.90% Gross Margin72.60% 52W Low113.09% ATR0.67
Employees21500 Current Ratio1.30 Sales Q/Q-11.10% Oper. Margin-5.20% RSI (14)67.83 Volatility2.52% 3.92%
OptionableYes Debt/Eq7.33 EPS Q/Q265.40% Profit Margin-15.00% Rel Volume0.58 Prev Close17.54
ShortableYes LT Debt/Eq7.24 EarningsAug 08 BMO Payout- Avg Volume23.24M Price17.71
Recom3.00 SMA203.69% SMA5020.45% SMA20020.19% Volume13,403,957 Change0.97%
Jun-16-17Initiated Cantor Fitzgerald Overweight $18
May-10-17Reiterated RBC Capital Mkts Sector Perform $18 → $19
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Jul-25-17 11:58AM  Things Are Looking Bullish for Valeant Pharmaceuticals Intl Inc (VRX) Ahead of Q2 Print SmarterAnalyst
Jul-24-17 12:30PM  Should You Buy Valeant Pharmaceuticals Intl Inc (VRX) Stock? 3 Pros, 3 Cons InvestorPlace
Jul-21-17 09:38AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Back From the Abyss InvestorPlace
06:00AM  Better Buy: Valeant Pharmaceuticals International, Inc. vs. Gilead Sciences Motley Fool
Jul-20-17 04:24PM  Sequoia Fund Seen Bouncing Back After Valeant Saga GuruFocus.com
Jul-19-17 02:03PM  Valeant Just Showed Why Its Share Price Has Deservedly Fallen by 93% Since August 2015 Motley Fool
11:37AM  When Should Investors Buy Options? Motley Fool
10:54AM  Valeant Pharmaceuticals Intl Inc (VRX) In Good Debt Shape, Vertex Pharmaceuticals Incorporated (VRTX) Wows with Triple CF Combo Success SmarterAnalyst
10:16AM  Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt Zacks
07:10AM  Featured Company News - Valeant Pharma Divests its Skin Care Business, Obagi Medical Products Business Accesswire
Jul-18-17 09:30AM  The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics Zacks
08:23AM  Street Talk: Tesla Inc (TSLA), Apple Inc. (AAPL), Valeant Pharmaceuticals Intl Inc (VRX) SmarterAnalyst
08:00AM  Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Impax Laboratories Accesswire
07:13AM  Valeant is meeting its debt goals, but core business is still struggling MarketWatch
06:00AM  The Unreformed Stock Picker: Without A Boss Bill Miller Is Betting On Amazon, Bitcoin And Bob Dylan Forbes
Jul-17-17 06:20PM  Valeant Takes Haircut on 2013 Obagi Deal as Debt Pile Looms, Divestitures Continue TheStreet.com
04:12PM  M&A Monday: Church & Dwight, Dominion Diamond, Valeant & More Investor's Business Daily
03:38PM  Pershing Square Sells $610 Million of Restaurant Brands, Stock Drops 2% Investopedia
11:41AM  Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back InvestorPlace
11:30AM  Valeant Unloads Yet Another Unit Barrons.com
09:30AM  Stocks to Watch: Procter & Gamble, Blue Apron, Netflix, Citigroup, BlackRock The Wall Street Journal
09:26AM  4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings Zacks
07:08AM  Valeant agrees to sell Obagi Medical Products for $190 million in cash MarketWatch
07:00AM  Valeant Agrees To Sell Obagi Medical Products Business CNW Group
05:57AM  Biotech Scoop: Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical (TEVA), and Kite Pharma (KITE) SmarterAnalyst
Jul-14-17 12:24PM  Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment TheStreet.com
09:35AM  J&J Psoriasis Drug Approval 'Another Negative' For Valeant Barrons.com
08:22AM  Valeant Pharmaceuticals Overall Trajectory Remains on Edge, Teva Pharmaceutical May Face Difficulty Beating Consensus SmarterAnalyst
Jul-13-17 06:33PM  Valeant Shaves Another Chunk From Its Crushing Debt Load, Shares Continue March Higher TheStreet.com
12:56PM  Valeant Pharmaceuticals Intl Inc (VRX) Pays Off Further Debt, Apple Inc. (AAPL) iPhone 8 Delay Rumors Swirl SmarterAnalyst
10:26AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is No Longer a Sewer InvestorPlace
10:04AM  Stocks to Watch: Snap, Target, Macy's, Delta, American Airlines, Valeant The Wall Street Journal
08:42AM  Valeant redeems $500 million of debt, on track to meet or exceed $5 billion debt reduction goal MarketWatch
08:30AM  Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018 PR Newswire
08:30AM  Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018 CNW Group
Jul-12-17 12:09PM  Valeant's Valuation 'Does Not Make Sense,' Warns Piper Jaffray Barrons.com
08:44AM  Has Valeant Pharmaceuticals Intl Inc (VRX) Stock Finally Bottomed? InvestorPlace
07:50AM  Featured Company News - Valeant Pharma Pays Off $811 Million in Terms Loans Accesswire
Jul-10-17 05:00PM  Valeant Announces Q2 2017 Financial Results Date And Conference Call Details PR Newswire
04:54PM  Valeant Continues Quest to Repay Massive $30 Billion Debt Load, Shares Close Higher TheStreet.com
11:52AM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Seeing a Lot of Quiet Buying InvestorPlace
07:08AM  Valeant pays down $811 million of term loans, shares rise MarketWatch
07:00AM  Valeant Pays Down $811 Million of Senior Secured Term Loans PR Newswire
Jul-07-17 09:43AM  4 Big Reasons Valeant Pharmaceuticals Skyrocketed 44% in June Motley Fool
08:00AM  Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Celsion Corporation Accesswire
Jul-06-17 11:13AM  Do Valeant Fundamentals Justify The Decrease In Bearish Sentiment? Benzinga
11:02AM  Valeant: A Long Road Ahead? Barrons.com
09:01AM  John Paulson Is Truly a Glutton for Punishment Motley Fool
07:00AM  Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses PR Newswire
Jul-05-17 01:00PM  Why Chesapeake Energy Corporation (CHK) Stock Isnt Coming Back Soon InvestorPlace
Jun-30-17 09:06AM  The Market In 5 Minutes Benzinga
07:57AM  [$$] Valeant After Ackman: Paulson Logs 26% Gain Barrons.com
07:00AM  Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International CNW Group
Jun-29-17 10:12PM  Sanpower's SVP Says Dendreon Deal Is a Milestone Bloomberg Video
05:13PM  Valeant Pharma Continues Asset Sales Instead of 'Riskier' Debt Swaps TheStreet.com
04:17PM  Benzinga's Option Alert Recap From June 29 Benzinga
02:00PM  Vulnerable Drugmakers Can't Shrug Off the FDA Bloomberg
12:01PM  3 Big Stock Charts for Thursday: Merck & Co., Inc. (MRK), Gilead Sciences, Inc. (GILD) and Valeant Pharmaceuticals Intl Inc (VRX) InvestorPlace
11:14AM  5 Reasons Valeant Can Keep Flying Barrons.com
10:49AM  Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA Zacks
10:28AM  Top 3 Companies Owned by Valeant (VRX) Investopedia
10:01AM  Valeant's Chart Is Actually Looking Pretty Good For A Change Benzinga
09:52AM  Valeant Could be Worth 30% More If It Can Continue to Execute Turnaround Efforts TheStreet.com
09:07AM  Your first trade for Thursday, June 29 CNBC
08:59AM  Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Untouchable InvestorPlace
08:50AM  Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop Benzinga
08:37AM  Sanpower Group Completes the Acquisition of Dendreon from Valeant PR Newswire
08:31AM  Morning Movers: Constellation Brands Jumps, Sarepta Climbs, Valeant Gains Barrons.com
07:00AM  Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group PR Newswire
07:00AM  Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group CNW Group
Jun-28-17 06:00PM  Salix Announces Filing Acceptance for PLENVU®* Next Generation Bowel Cleansing Preparation for Colonoscopies PR Newswire
05:59PM  "Fast Money" final trades: TBT, VRX, and more CNBC Videos
05:45PM  Cantor Boosts Price Target for Valeant Pharmaceuticals Intl Inc; Heres Why SmarterAnalyst
05:15PM  Paulson Dives Deeper Into Valeant With Increased Holding GuruFocus.com
04:50PM  Will Valeants Lenders Have to Take a Haircut Through Debt-Equity Swap? SmarterAnalyst
05:47AM  Valeant Most Exposed With FDA Generics Push Investopedia
Jun-27-17 02:02PM  Valeant: Out of the Frying Pan, Into the Fire Barrons.com
10:27AM  Go Long Valeant Pharmaceuticals Intl Inc (VRX) Stock Even After This Rip InvestorPlace
09:51AM  Bill Ackman's Big Triumph Becomes His Big Problem Bloomberg
09:49AM  Paulson Ups Valeant Stake; Activist Investor Targets Nestle -- ICYMI Monday TheStreet.com
08:33AM  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock? Zacks
Jun-26-17 09:32PM  Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers TheStreet.com +8.10%
05:28PM  Valeant: Paulson & Co. Puts (a Bit More) Money Where its Mouth is Barrons.com
05:27PM  Hedge fund Paulson & Co discloses 6.3 percent stake in Valeant Reuters
04:55PM  Paulson Boosts His Stake in Valeant Pharmaceuticals to 6.3% Bloomberg
04:38PM  Biden tells Ackman never disrespect memory of his dead son MarketWatch
04:31PM  Why Rite Aid, Valeant Pharmaceuticals, and Hertz Global Holdings Jumped Today Motley Fool
04:24PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock Could Have 30% Upside InvestorPlace
02:17PM  Valeant Pharma: A Debt Swap? Barrons.com
01:08PM  3 Cheap Healthcare Stocks You Can Buy Right Now Motley Fool
11:29AM  Billionaire Ackman Could Win Big on Blackstone's Platform Buy Investopedia
11:02AM  CANADA STOCKS-TSX down as softer commodity prices weigh on resource shares Reuters
Jun-23-17 04:02PM  Paulson Times Appointment to Valeant's Board Perfectly Motley Fool
11:54AM  Nvidia Corporation (NVDA) Stock Is Too Hot. Buy This Instead. InvestorPlace
09:06AM  What Bill Miller Thinks about Valeant Now Market Realist
Jun-22-17 04:40PM  Why Barnes & Noble, SunPower, and Valeant Pharmaceuticals Jumped Today Motley Fool +13.30%
12:08PM  Hospitals Rise on Senate Health Bill But Long-Term Prognosis in Question Barrons.com
11:38AM  Does Valeant Pharmaceuticals Intl Inc (VRX) Stock Have a Bull Case? InvestorPlace
08:01AM  Donald Trump Softens Stance on Drug Prices, Sends Biotech Stocks Soaring Motley Fool
07:30AM  Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International PR Newswire
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMay 11Buy13.9020,000278,00070,572May 15 05:19 PM
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM